Management of Suspected Bladder Cancer in Elderly Patients

Priority Laboratory Evaluations

The National Comprehensive Cancer Network recommends obtaining liver function tests, including lactate dehydrogenase (LDH), alkaline phosphatase, and calcium, to evaluate for potential metastatic disease 1
The National Comprehensive Cancer Network suggests ordering additional imaging studies, such as a CT scan of the chest, abdomen, and pelvis, to complete staging evaluation for suspected bladder cancer 2
Consider bone scan if alkaline phosphatase is elevated or if the patient reports bone pain, as recommended by The Journal of Urology 3

Elevated liver enzymes, such as ALT and AST, with normal bilirubin, may suggest non-alcoholic fatty liver disease, consistent with ultrasound findings, according to The Journal of Urology 3
Monitor liver function tests closely, as they may impact chemotherapy options, as recommended by the National Comprehensive Cancer Network 2
Patients with Stage 3B chronic kidney disease (CKD) and creatinine of 1.94 mg/dL, and eGFR of 35 ml/min, should be referred to nephrology for management of CKD, as appropriate nephrology referral may help prevent further deterioration of renal function, according to The Journal of Urology 4

Complete staging with CT scan of chest, abdomen, and pelvis is essential before finalizing treatment plan, as recommended by the National Comprehensive Cancer Network 2
Biopsy results from the urologist will determine definitive treatment approach, according to the National Comprehensive Cancer Network 5
Patients with renal impairment (eGFR 35 ml/min) are ineligible for cisplatin-based chemotherapy, and carboplatin/gemcitabine (CG) is the preferred regimen with a more favorable toxicity profile, as recommended by Annals of Oncology 6
Single-agent therapy, such as gemcitabine or taxane, may be considered if the patient cannot tolerate combination therapy, according to Annals of Oncology 6

Advanced age (90 years) combined with CKD and anemia requires careful consideration of treatment toxicity versus benefit, as recommended by Annals of Oncology 6
Performance status assessment is crucial for determining treatment intensity, according to Annals of Oncology 6
Palliative approaches, including radiotherapy, may be appropriate for symptom control, as recommended by Annals of Oncology 6

Schedule follow-up within 1-2 weeks to review results of additional testing and urologist consultation, as recommended by the National Comprehensive Cancer Network 5
Monitor renal function, electrolytes, and complete blood count regularly during treatment, according to The Journal of Urology 4
Adjust treatment plan based on biopsy results, complete staging, and patient's performance status, as recommended by the National Comprehensive Cancer Network 5